阿奇霉素治疗肺炎支原体肺炎的临床效果观察

摘要

Objective On patients with mycoplasma pneumonia clinical drug research, understand the superiority of azithromycin relative to erythromycin lactate. Methods Select our hospital from March 2012 to March 2014 the two years of mycoplasma pneumonia treated over a period of time, a total of 68 people, will be randomly divided into control group and observation group, each group of 34 people.The control group treated with erythromycin lactate, observation group with azithromycin treatment, compared two groups of patients treatment effectiveness and clinical manifestations, understand the azithromycin existence superiority. Results The treatment effect, the control group total effective rate of only 85.3%, while the observation group reached 93.6%, both comparisons show signiifcant difference (P<0.05); clinical manifestations, observation group of patients, cough ease, the body temperature is back to normal lung's disappearing and hospitalization time were shorter than that in control group, azithromycin treatment effect is better.Conclusion Azithromycin can effectively improve pulmonary function, regulate body temperature, let patients to restore health as soon as possible, suited to be used widely in clinical treatment.%目的：针对患有支原体肺炎的患者展开临床用药研究，了解阿奇霉素相对于乳酸红霉素的优越性。方法选取我院在2012年3月至2014年3月这两年时间内收治的支原体肺炎患者共68例，将其随机分为对照组及观察组，每组34例。对照组患者用乳酸红霉素治疗，观察组患者用阿奇霉素治疗，对比两组患者治疗有效性以及临床表现，了解阿奇霉素是否存在优越性。结果治疗效果方面，对照组总有效率为仅为85.3%，而观察组患者总有效率达到了93.6%，二者对比呈显著性差异（P＜0.05）；临床表现方面，观察组患者在体温恢复正常、咳嗽缓解、肺部啰音消失以及住院治疗方面时间均短于对照组，说明阿奇霉素治疗效果更优。结论阿奇霉素能够有效改善患者肺部功能，调节体温，让患者尽快恢复健康状态，适合在临床治疗中推广使用。